R
Reistone Biopharma
Focusing on rapidly developing innovative medicines through global collaborations within Research and Development
About Reistone Biopharma
Reistone Biopharma is a clinical-stage biopharmaceutical company that develops medicines for autoimmune and inflammatory diseases. The company has a particular focus on inflammatory bowel disease.
Founded in January 2018, Reistone Biopharma operates in Shanghai and Beijing, China, and Boston, USA. The company is actively engaged in clinical trials, including a successful Phase 2 trial for its JAK inhibitor for patients with moderate-to-severe ulcerative colitis. In May 2022, the company announced the completion of a Series A financing round of nearly USD 100 million, led by Huagai Capital.
Reistone Biopharma's business model is centered on the research and development of novel drugs to address unmet medical needs in the autoimmune and inflammatory disease market. The company's primary clients are patients suffering from these conditions, and it operates within the global biopharmaceutical industry.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2022 | $100M | $400M | Zero2IPO · Zhangjiang Haoheng · Hanne Capital · YUNION Healthcare Fund | ↗ |
Growth signals
Latest recorded traffic for Reistone Biopharma is 710 monthly website visits, up 108.8% over the last three months. Reistone Biopharma's team grew 3.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Reistone Biopharma in the Huangpu ecosystem
The Reistone Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Huagai Capital
Zero2IPO- ZHZhangjiang Haoheng
Hanne Capital- YFYUNION Healthcare Fund
- CFCapital Healthcare Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Reistone Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reistone Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









